Long-term infectious complications and their relation to treatment duration in catheter-related Staphylococcus aureus bacteremia.
Publication year
2001Source
European Journal of Clinical Microbiology and Infectious Diseases, 20, 6, (2001), pp. 380--4ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Haematology
Journal title
European Journal of Clinical Microbiology and Infectious Diseases
Volume
vol. 20
Issue
iss. 6
Page start
p. 380-
Page end
p. 4
Subject
HaematologyAbstract
The optimal duration of treatment for catheter-related Staphylococcus aureus bacteremia is not known. Short courses (< or = 2 weeks) of therapy should be viewed with caution because essential data on late complications, such as osteomyelitis and metastatic abscesses, are lacking. This study represents a retrospective analysis of the data from 49 adult patients hospitalised in the period 1994-1996 (mean age, 57 years; range, 20-90 years; 47% male) and from whom Staphylococcus aureus was cultured concomitantly from peripheral blood and catheter segments. Forty-six venous catheters, two arterial catheters, and one unknown type of catheter were used. Forty-four patients were treated with effective anti-Staphylococcus aureus antibiotics. Twenty patients had a favourable outcome, defined as no complication and no death during 1 year of follow-up, 24 patients had complications, 14 patients died due to attributable mortality, and 5 other patients died of an underlying disease without showing signs or symptoms of a complication. Patients were categorised according to the duration of treatment. There were small differences between a shorter (1-14 days) and a longer (>14 days) course of antibiotics with regard to favourable outcome (41% vs. 33%), complications (48% vs. 53%), attributable death (31% vs. 20%), and death due to underlying disease (41% vs. 33%), respectively. The rates of complications and death were high, but a definite conclusion cannot be drawn because the study was underpowered. More randomised trials are needed, but, until the results of such trials are available, the duration of therapy should not be shortened to less than 14 days.
This item appears in the following Collection(s)
- Academic publications [234412]
- Faculty of Medical Sciences [89250]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.